CONCORD biomarker prediction for novel drug introduction to different cancer types.

Oncotarget · 2018 · PMC5787421 · PMID 29416679

Europe PMC DOI

hedged sentences

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

marginally significantp=0.072so close (0.05 < p ≤ 0.1)

We confirmed that there were, at least, marginally significant differences in overall survival for Hummel-110 [ 43 ] (p=0.072) and Lenz-414 [ 44 ] (p=0.036).

also in 26,082 other papers

highly significantno p-value reported

Three-way COXEN biomarker identification Once a different cancer type was selected for CONCORD modeling, we further triaged the initial in vitro predictive biomarkers of drug response into the ones that retained highly significant COXEN coefficients across all the three pairs among cancer cell line, original cancer, and different cancer patient sets defined as COXEN sets in Supplementary Table 6 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.